Antioxidant activity:
Bilberry anthocyanins and some related aglycones are reported to be potent scavengers of free radicals, as when tested in vitro in the superoxide anion generating system hypoxanthine/xanthine oxidase.^(1,2) Anthocyanin extracts of Vaccinium myrtillus fruits have been shown to act both as scavengers against superoxide anion and as inhibitors of lipid peroxidation in rat liver microsomes.^(3-5)
Cyanidin and delphinidin chlorides proved to be potent scavengers, interacting with 1,1-diphenyl-1-picrylhydrazyl (DPPH) free radical: the IC50 values were 2.5 and 4.0 µM, respectively, comparable to that of quercetin. 
Cyanidin chloride is the most active compound on CCl4 induced lipoperoxidation.⁽⁶⁾
Laplaud et al.⁽⁷⁾ reported that an aqueous extract of V. myrtillus berries protected low-density lipoproteins (LDL) from copper-mediated oxidation.
As reported by Rasetti et al.⁽⁸⁾ a proprietary Bilberry extract was capable of protecting apolipoprotein B from UV-induced oxidative fragmentation.
Ichiyanagi et al.⁽⁹⁾ studied the activity of 11 major bilberry anthocyanins against hydroxyl radicals (OH°), superoxide anion, and singlet oxigen by using capillary zone electrophoresis. The reactivity of anthocyanins towards OH° was comparable to that of (+)-catechin used as reference substance, and was neither significantly affected by the aglycon structure nor by the conjugated sugar type. On the contrary, the reactivity towards superoxide anion and singlet oxygen were determined by the aglycon structure.
Prior et al.⁽¹⁰⁾ comparing the antioxidant capacity (oxygen radical absorbance capacity, ORAC) of different variety of four Vaccinium species found that V. myrtillus and V. angustifolium (low bush) exhibited potent ORAC activity (44.6±2.3 and 45.9±2.2, respectively).
A linear relationship existed between ORAC and anthocyanin (rxy = 0.77) or total phenolic content (rxy = 0.92).
Anthocyanins can also prevent the oxidation of ascorbic acid caused by metal ions by chelating the metals ions and forming an ascorbic acid (copigment)-metal-anthocyanin complex.⁽¹¹⁾ In addition the anthocyanin extract is reported to inhibit the K+ loss induced by free radicals in human erythrocytes as well as the cellular reactions induced by the oxidative compounds daunomycin and paraquat.^(12,13)

Kidney protection Most recent studies⁽¹⁴⁾ indicate that Mirtoselect^® is active in protecting the kidneys form damage induced by potassium bromate in mice. Potassium bromate is an environmental pollutant, which can be formed as a by-product in the process of ozone purification of drinking water. It may form free radicals triggering harmful modifications in the kidney tissue.
The protective properties of bilberry extract are due to the improved antioxidant capacity of the kidney tissue promoted by bilberry anthicyanins: the reduction of NO production and the improved ability to absorb oxygen radical (ORAC).

Inhibition of cyclic nucleotide phosphodiesterases:
The anthocyanins cyanidin, delphinidin and malvidin 3-O-glucosides and their aglycones are reported to inhibit phosphodiesterase (PDE) isoforms from different sources as retina, choroid, large vessels and platelets. The compounds were more active on retinal than on platelet PDEs and in particular on the retinal calmodulin stimulated enzymes. IC50 of malvidin and delphinidin 3-O-glucosides on calmodulin stimulated enzymes ranged from 5.4 to 35.6 µM. Anthocyanins appeared more active than isobutylmethylxanthine used as reference.^(15-17)

Antiplatelet activity:
Morazzoni and Magistretti⁽¹⁸⁾ studied the antiplatelet activity of Bilberry 36% extract against aggregation induced by ADP, collagen and sodium arachidonate on rabbit platelet-rich plasma (PRP). Bilberry extract was a strong inhibitor of platelet aggregation with IC50 values ranging from 0.36 to 0.81 mg/mL PRP, comparable to those obtained with dipyridamole. Moreover, the Bilberry extract exerted an inhibitory effect on ADP-induced platelet aggregation in rats maintained on extracorporeal circulation.
The Bilberry extract when orally administered to rats at doses up to 400 mg/kg, prolonged bleeding time for 24 h, without affecting blood coagulation pathways; administration of 400 mg/kg by oral route to mice, reduced the adhesiveness of platelets to glass micropellets. An anthocyanin extract of V. myrtillus fruits was reported to inhibit platelet aggregation in vitro when induced by ADP or adrenalin on human plasma.⁽¹⁹⁾ The inhibitory effect on platelet aggregation, demonstrated in vitro, was confirmed ex vivo on ADP- and collagen-induced aggregation of platelets obtained from the blood of 30 healthy subjects treated by oral route (480 mg/day for 30-60 days).⁽²⁰⁾

Interaction with collagen, phospholipids and proteoglycans:
In vitro anthocyanin extracts of V. myrtillus fruits are able to inhibit proteolytic enzymes like elastase, which are involved in the degradation of collagen and other components of the extravascular matrix in certain pathological conditions such as atherosclerosis, pulmonary emphysema, rheumatoid arthritis.⁽²¹⁾ Anthocyanin extracts may interact with collagen metabolism, by cross-linking collagen fibres and making them more resistant to collagenase action.⁽²²⁾ A reduction in biosynthesis of polymeric collagen and structural glycoproteins, responsible for thickening of capillary in diabetics, has also been described.⁽²³⁾ Hystochemical and biochemical studies showed that anthocyanins from V. myrtillus interact with phospholipidic constituents of plasma membranes from the rat brain, potentially modifying their physical chemical properties and enhancing their resistance to lesive stimuli.⁽²⁴⁾ Salmona et al.⁽²⁵⁾ studied the influence of Bilberry 36% extract on membrane viscosity of platelets and confirmed that anthocyanins were able to modify the membrane fluidity due to their high affinity for membrane phospholipids.

A local stimulating effect of the anthocyanins from V. myrtillus on the biosynthesis of mucopolysaccharides in granuloma induced by foreign bodies was reported by Mian et al.⁽²⁶⁾ Mucopolysaccharides are recognised to play an important role in maintaining the integrity of both perivascular tissue and the basal membrane. In an in vitro study, using endothelial cells from human umbilical cord, Piovella et al.^(27,28) reported that anthocyanins induced active phagocytosis of pigment material and intense cell regeneration. A growth promoting activity on fibroblasts and on smooth muscle cells was also reported in the same study.
Anthocyanins may facilitate the regeneration both of the cellular component of the vessel wall and of the perivascular tissues, due to their stimulating effect on mucopolysaccharides.

Effect on arteriolar vasomotion:
The arteriolar vasomotion, a rhythmic variation of diameter of arterioles in microvascular network, influences the microvascular mechanism which regulates the formation of interstitial fluid. Colantuoni et al.⁽²⁹⁾ studied the effects of Bilberry 36% extract on arteriolar vasomotion in two experimental models: the cheek pouch of anaesthetised hamster and the skin fold window preparation (muscular type) of unanaesthetised hamster. Bilberry 36% extract (5-10 mg/kg i.v.) induced vasomotion suppressed by anaesthetic in cheek pouch arterioles and terminal arterioles, and increased vasomotion frequency in the skeletal muscle arteriolar network. These findings indicate that the Bilberry extract may prevent or control interstitial fluid formation and contribute to control the blood flow redistribution in the microvascular network.

1. Salvayre R., Braquet P., Perruchot Th., Douste-Blazy L., in « Flavonoids and Bioflavonoids, 1981 », L. Farkas, M. Gábor, F. Kállay, H. Wagner (Eds), Elsevier, Amsterdam, 1982, pp 437-442. 
2. Acquaviva R., Russo A., Galvano F., Galvano G., Barcellona M.L., Li Volti G., Vanella A., Cell. Biol. Toxicol. 19, 243 (2003).
3. Meunier M.T., Duroux E., Bastide P., Plant médicin. Phytothér. 23, 267 (1989).
4. Martín-Aragón S., Basabe B., Benedí J.M., Villar A.M., Phytother. Res. 12 Suppl.1, Second International Symposium on Natural Drugs, 1997, S104-S106 (1998).
5. Martín-Aragón S., Basabe B., Benedí J.M., Villar A.M., Pharm. Biol. 37, 109 (1999).
6. Morazzoni P., Malandrino S., Pharmacol. Res. Comms. 20, Suppl. 2, 254 (1988).
7.. Laplaud P.M., Lelubre A., Chapman M.J., Fundam. Clin. Pharmacol. 11, 35 (1997).
8. Rasetti M.F., Caruso D., Galli G., Bosisio E., Phytomedicine 3, 335 (1996/97).
9. Ichiyanagi T., Hatano Y., Matsugo S., Konishi T., ITE lett. Batt., New Tech. & Med. 4, 788 (2003).
10. Prior R.L., Cao G., Martin A., Sofic E., McEwen J., O’Brien C., Lischner N., Elhenfeldt M, Kalt W., Krewer G., Mainland C.M., J. Agric. Food Chem. 46, 2686 (1998).
11. Sarma A.D., Sreelakshmi Y., Sharma R., Phytochemistry 45, 671 (1997).
12. Maridonneau I., Braquet P., Garay R.P. in "Flavonoids and Bioflavonoids, 1981", L. Farkas, M. Gábor, F. Kállay, H. Wagner (Eds), Elsevier, Amsterdam, 1982, pp 427-436.
13. Mavelli I., Rossi L., Autuori F., Braquet P., Rotilio G., in "Oxy Radicals Their Scavenger Syst.", Proc. Int. Conf. Superoxide Dismutase, 3dr 1982 , G. Cohen , R.A. Greenwald , Elsevier, New York, 1983, pp 326-329.
14. Bao L., Yao XS., Tsi D., Yau CC., Chia CS., Nagai H., Kurihara H., J. Agric. Food Chem., 56, pag. 420-425 (2008)
15. Ferretti C., Magistretti M.J., Robotti A., Ghi P., Genazzani E., Pharmacol. Res. Commun. 20, Suppl. 2, 150 (1988).
16. Ferretti C., Blengio M., Malandrino S., Pifferi G., XIth International Symposium on Medicinal Chemistry, Jerusalem, Israel, September 2-7 (1990).
17. Pifferi G, Malandrino S., Morazzoni P., Ferretti C., XVIth International Conference of the Groupe Polyphenols, Lisbon, July 13-16, 1992 - Polyphenols Actualities 8, 60 (1992).
18. Morazzoni P., Magistretti M.J., Fitoterapia 61, 13 (1990).
19. Serranillos M.G., Zaragoza F., Alvarez P., An. Real. Acad. Farm. 49, 79 (1983).
20. Pulliero G., Montin S., Bettini V., Martino R., Mogno C., Lo Castro G., Fitoterapia 60, 69 (1989).
21. Jonadet M., Meunier M.T., Bastide J., Bastide P., J. Pharm. Belg. 38, 41 (1983).
22. Robert A.M., Miskulin M., Godeau G., Tixier J.M. in "Frontiers of Matrix Biology", L. Robert (Ed), Vol. 7, Karger, Basel, 1979, pp 336-349.
23. Boniface R., Miskulin M., Robert L., Robert A.M., "Flavonoids and Bioflavonoids, 1985", L. Farkas, M. Gábor, F. Kallay (Eds), Elsevier, Amsterdam-Oxford-New York-Tokio 1986, pp 293-301.
24. Curri B.S., Bombardelli E., Therapia Angiol. 32, 117 (1976).
25. Salmona M., Masturzo P., Cini M., Morazzoni P., Magistretti M.J., in "Flavonoids in Biology and Medicine III: Current Issues in Flavonoids Research.", N.P. Das (Ed.), Singapore 1990, pp 475-480.
26. Mian E., Curri B.S., Lietti A., Bombardelli E., Min. Med. 68, 3565 (1977).
27. Piovella C., Curri B.S., Piovella M., Piovella F., Therapia Angiol. 35, 119 (1979).
28. Piovella F., Ricetti M.M., Almasio P., Feoli F.R., Pesenti Campagnoni M., Castagnola C., Min. Angiol. 6, 135 (1981).
29. Colantuoni A., Bertuglia S., Magistretti M. J., Donato L., Arzneim. Forsch. 41, 905 (1991).